Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 4, p. s226, 2023. DOI: 10.25251/skin.7.supp.226. Disponível em: https://skin.dermsquared.com/skin/article/view/2193. Acesso em: 30 may. 2025.